Your Ovaries Are Running the Show (And Nobody Told You)

The longevity industry just discovered what your body has known all along.
By a woman in her forties who is absolutely fine, thank you for asking

I turned 44 last month. I celebrated by Googling “perimenopause brain fog” at 2am while forgetting what I’d gone into the kitchen for. Twice. The Google rabbit hole, as it does, took me somewhere I wasn’t expecting: not to a listicle about evening primrose oil, but into the science, which made me sit up straight and put the phone down. Everything the wellness industry has been doing for women and ageing has been, more or less, wrong. Or at least, criminally incomplete.

Welcome to the ovarian longevity revolution. Please, take a seat. There’s a lot to get to.

The Penny That Dropped

Here’s the thing that nobody mentioned to me in all my years of annual check-ups, smear tests, and well-meaning conversations with GPs: the ovary is the central reproductive and endocrine organ in women, responsible not just for producing eggs but for secreting the steroid hormones that regulate systemic physiological processes throughout the entire body. The entire body. Not just the reproductive bits.

The ovary is among the first organs to exhibit signs of ageing, with a noticeable decline in fertility beginning in the late twenties and accelerating after 35. Menopause, typically occurring around age 51, marks the near-complete cessation of ovarian function and a sharp drop in oestrogen levels. And this accelerated decline sits in stark contrast to our lengthening lifespans, making ovarian ageing a critical determinant of women’s healthspan and quality of life.

So. We’re living longer than ever. And our ovaries are checking out earlier than ever, proportionally speaking. And nobody thought this was worth a serious scientific conversation until roughly… now.

I’d like to be gracious about this. I am trying.

“The ovaries are like conductors in an orchestra. They’re coordinating things like bone health, heart health, and metabolism.”
Dr Jennifer Garrison, UCSF

What the Longevity Bros Forgot to Mention

The longevity space has had a bit of a moment lately: cold plunges, NAD+ supplements, continuous glucose monitors, men in their fifties posting their VO2 max scores on LinkedIn. Jolly good. Very inspiring. But here’s the awkward truth: the booming longevity market, like medicine decades before it, has been tacitly male. Women’s health has largely been extrapolated from men’s data and protocols designed for men.

According to the World Economic Forum’s Gender Health Gap Report, women spend approximately 25% more of their lives in poor health than men. We’re living longer, just not necessarily better. Which is (and I’m choosing my words carefully here) not the vibe.

A Deloitte analysis found that women’s health represented just 2% of the $41.2 billion in health venture capital investment in 2023. Two percent. For half the population. I’d make a joke here, but honestly I’m just tired.

The good news is this is shifting. Quickly.

The Ovary as Command Central

While once thought of as vehicles for fertility, the ovaries are being scientifically recognised as contributors to much more in women’s health. Neuroscientist Dr Jennifer Garrison, faculty member at UCSF and co-lead of the XPRIZE Ovarian Health competition, has described them as the “pacemaker for ageing” in women: not an isolated reproductive organ but a systemic regulator with downstream effects on cardiovascular, neurological, and metabolic health.

Declining ovarian function accelerates not only reproductive senescence but also contributes to age-related disorders including osteoporosis, neurodegenerative diseases, and cardiovascular conditions. So when your ovaries start winding down, they don’t just affect your periods or your fertility. They affect your brain, your heart, your bones, and your immune system. They’re not a single instrument; they’re the conductor of the entire orchestra.

By their mid-thirties most women experience a decline in fertility, and by age 50, after menopause, many face cardiovascular, bone, cognitive, and immune health issues tied to the loss of hormones.

And for most of us, the first we hear about any of this in a meaningful clinical context is when the symptoms have already landed and we’re standing in a GP’s office being handed a pamphlet about HRT.

The Hot Takes and the Heated Debate

Here’s where I have to be honest with you: this field is moving fast, and not everyone agrees on where it’s headed.

Some researchers and clinicians are electrified by the potential of what’s being called “ovarian longevity medicine.” In April 2025, women’s health biotech Granata Bio acquired Oviva Therapeutics, a company developing OVI-586, a first-in-class therapeutic designed to enhance women’s healthspan by extending ovarian function through modulation of anti-Müllerian hormone (AMH). The science behind it is compelling: AMH acts at the earliest stages of follicle development, potentially preserving the ovarian reserve and, by extension, the endocrine functions that protect everything from bone density to cognitive health.

Researchers at Columbia University are investigating how “geroprotectors” (compounds targeting the hallmarks of ageing) might delay ovarian ageing, promoting reproductive health and extending healthspan and longevity in women.

Meanwhile, the equally reasonable camp of scientists and clinicians would like everyone to slow down, please, because mouse studies are not women, and we’ve been burned before by overpromising hormonal interventions. The HRT saga of the early 2000s, where a large study spooked millions of women off hormone therapy based on findings that were later substantially nuanced, still casts a long shadow. Trust, once lost, takes time.

“The goal is to make the function of our organs match the way that we’re living.”
Dr Francesca Duncan, Northwestern University

As Dr Francesca Duncan from Northwestern University’s Feinberg School of Medicine points out, one of the persistent misconceptions is the knee-jerk assumption that the goal must be to make women in their sixties, seventies, or eighties pregnant or fertile. That is emphatically not the goal. The goal is to make the function of our organs match the way that we’re living.

The distinction isn’t trivial. This isn’t about extending reproductive years for their own sake. It’s about extending the years you spend feeling well.

What’s Actually Available Right Now

This is the part where I temper my own enthusiasm, because I know how easy it is to read about exciting emerging science and immediately ask your GP for the experimental AMH drug they’ve never heard of.

What’s actually on the shelves right now is considerably less dramatic. Cycle-synced nutrition, nervous system regulation, biofeedback, and a proactive rather than reactive approach to hormonal health (understanding your hormonal baseline decades before you hit a transition point) are about as glamorous as they sound, which is to say, not especially. But they’re what we have, and there’s growing evidence behind them.

At-home diagnostic tracking, testing, and preventive screening are entering the market at pace, and platforms centring women’s midlife health are attracting serious investment. The idea being that you don’t wait until the symptoms to start the conversation.

There’s also HRT, which (and this is where the debate genuinely hots up) has undergone significant rehabilitation since the 2000s scare. Many clinicians now argue it was underused for a generation of women who suffered unnecessarily. Others maintain that individual risk profiles make broad recommendations dangerous. Both positions have merit. Both are held by smart people. Your mileage, quite literally, may vary.

The Part That Keeps Me Up at Night (More Than the Hot Flushes)

XPRIZE has launched a new Ovarian Health competition with a $50 million prize purse, challenging innovators worldwide to develop better tools to measure and support ovarian health. The goal: convert invisible signals into breakthroughs for disease prediction and care, and ultimately close the gender health gap in a field that has long been, as XPRIZE itself notes, “overlooked.”

Fifty million dollars is a lot of money. It’s also a fraction of what gets poured into cardiovascular research, or cancer, or frankly any condition that affects men in comparable numbers. The disparity in research investment isn’t just a feminist talking point; it’s a public health problem with real costs attached.

Research on ovarian ageing remains fragmented and lacks integrative analysis, meaning even the experts don’t yet have the full picture. We’re working with pieces of a puzzle, and some of the pieces are still being cut.

What I Actually Think

I promised you I wouldn’t take a position, and I’m going to honour that. Mostly.

What I will say is this: the fact that we’re having this conversation at all, seriously, scientifically, with real money and real urgency behind it, feels like something. Something that women in their forties sitting awake at 2am with a phone and a lot of questions absolutely deserve.

Whether the future lies in AMH therapeutics, geroprotectors, telehealth hormone platforms, or something we haven’t named yet, the shift in framing is already significant. In 2026, longevity is pivoting toward women’s healthspan, moving beyond managing menopause symptoms to addressing ovarian ageing itself, with interventions tailored to women at every life stage.

Not “managing” symptoms. Addressing the underlying mechanism. That’s a different sentence, and it opens a different conversation entirely.

My ovaries have apparently been running the show for 44 years. It seems only fair that science finally RSVPed.